© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
January 17, 2022
Ghassan K. Abou-Alfa, MD, discusses the use of tislelizumab as treatment of patients with unresectable hepatocellular carcinoma, as investigated in a phase 2 clinical trial.
October 20, 2021
Ghassan K. Abou-Alfa, MD, reviews the liver cancer landscape and the collaboration of Memorial Sloan Kettering Cancer Center with other institutions to further treatments in this setting.
June 23, 2021
Ghassan K. Abou-Alfa, MD, MBA, shares clinical pearls and advice for the management of patients with unresectable HCC.
Gastrointestinal oncology expert, Dr Ghassan K. Abou-Alfa, discusses future directions and promising novel approaches under investigation for the treatment of unresectable HCC.
Dr Ghassan K. Abou-Alfa provides insight from the results of the REFLECT trial comparing sorafenib vs lenvatinib in patients with unresectable HCC and comments on the safety profile of lenvatinib.
An expert in gastrointestinal oncology comments on approaching first-line therapy for a patient with previously untreated, unresectable HCC and reviews key findings from the IMbrave150 trial.